Drug intelligence / Profile preview

SIRT6-aav.017

Development stage
Preclinical
Lead developer
SirtLab
Modality
Gene Therapies
Administration
Intravenous
01

Overview

SIRT6-aav.017 is a recombinant adeno-associated virus (rAAV) gene therapy candidate developed by SirtLab for the treatment of neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The therapeutic approach involves the delivery of the SIRT6 gene to the central nervous system to achieve sustained expression of the SIRT6 protein. SIRT6 is a member of the sirtuin family of NAD+-dependent deacetylases that plays a critical role in DNA repair, genomic stability, and metabolic homeostasis. By enhancing SIRT6 levels, the therapy aims to provide neuroprotective effects and counteract the cellular aging processes associated with neurodegeneration. SIRT6-aav.017 is currently in preclinical development, having demonstrated proof-of-concept in animal models.

Other names
SIRT6-rAAVSIRT-6-rAAVSIRT 6-rAAVrAAV Alzheimer's DiseaserAAV Amyotrophic Lateral Sclerosis
02

Targets

SIRT6 (Sirtuin 6)

Beyond the preview

Go deeper on SIRT6-aav.017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIRT6-aav.017.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call